Brokers Set Expectations for SNDX Q1 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a research report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will earn ($1.11) per share for the quarter. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals’ Q2 2025 earnings at ($1.11) EPS.

A number of other equities research analysts have also recently commented on SNDX. JPMorgan Chase & Co. increased their target price on Syndax Pharmaceuticals from $35.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday. Scotiabank reduced their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. The Goldman Sachs Group increased their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, Citigroup reduced their price target on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Syndax Pharmaceuticals Stock Performance

Shares of NASDAQ:SNDX opened at $14.29 on Wednesday. The business’s fifty day moving average price is $14.31 and its two-hundred day moving average price is $16.68. The stock has a market cap of $1.22 billion, a PE ratio of -3.94 and a beta of 0.90. Syndax Pharmaceuticals has a one year low of $12.06 and a one year high of $25.16.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The business had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $86.32 million.

Insider Buying and Selling

In other Syndax Pharmaceuticals news, CEO Michael A. Metzger sold 13,288 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the transaction, the chief executive officer now directly owns 300,121 shares of the company’s stock, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Keith A. Goldan sold 3,777 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the transaction, the chief financial officer now directly owns 90,746 shares in the company, valued at $1,406,563. This trade represents a 4.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new stake in shares of Syndax Pharmaceuticals during the fourth quarter valued at about $26,000. Quantbot Technologies LP acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter valued at about $49,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after acquiring an additional 541 shares in the last quarter. Virtus ETF Advisers LLC grew its stake in shares of Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company’s stock valued at $70,000 after acquiring an additional 827 shares in the last quarter. Finally, Cape Investment Advisory Inc. grew its stake in shares of Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company’s stock valued at $85,000 after acquiring an additional 3,927 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).